Roche's Columvi Meets Main Goal in Lymphoma Phase 3 Trial
By Adria Calatayud
Roche Holding said its Columvi drug helped lymphoma patients who had received at least one prior treatment live longer in a phase 3 clinical trial, meeting the primary goal of the study.
The Swiss pharmaceutical giant said Monday that Columvi, in combination with chemotherapy, showed a statistically significant improvement in overall survival for people with diffuse large B-cell lymphoma--a form of blood cancer--who had received at least one prior line of therapy and weren't candidates for transplant of their own stem cells.
Roche said safety of the drug combination appeared consistent with the known safety profiles of the individual medicines.
Data from the trial will be submitted to health authorities, the company said. Roche intends to publish more details at an upcoming medical meeting, it said.
Columvi already received approval by the U.S. Food and Drug Administration and conditional authorization from the European Commission to treat people with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of therapy, Roche said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 15, 2024 01:39 ET (05:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
What’s Happening In the Markets This Week
-
What Does Nvidia’s Stock Split Mean for Investors?
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
The 10 Best Dividend Stocks
-
The Most Attractive Investment Opportunities in Oil & Gas
-
Apple: Generative AI Strategy Should Drive Sales and Upgrades
-
2 Undervalued Stocks That Just Raised Dividends
-
2 Popular Stocks That Top Managers Are Selling
-
The Best REITs to Buy
-
Nio Earnings: Revenue and Loss Largely In Line, but Vehicle Margin Missed Amid Price Competition
-
The Best Biotech Stocks to Buy